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PROGRESS IN GERIATRICS
The Diagnosis and Treatment of Elderly Patients with Acute
Exacerbation of Chronic Obstructive Pulmonary Disease and
Chronic Bronchitis
Timothy E. Albertson, MD, MPH, PhD,w Samuel Louie, MD,w and Andrew L. Chan, MB, ChBw
The syndrome of chronic obstructive pulmonary disease
(COPD) consists of chronic bronchitis (CB), bronchiectasis,
emphysema, and reversible airway disease that combine
uniquely in an individual patient. Older patients are at risk
for COPD and its componentsFemphysema, CB, and
bronchiectasis. Bacterial and viral infections play a role in
acute exacerbations of COPD (AECOPD) and in acute ex-
acerbations of CB (AECB) without features of COPD.
Older patients are at risk for resistant bacterial organisms
during their episodes of AECOPD and AECB. Organisms
include the more-common bacteria implicated in AECOPD/
AECB such asHaemophilus influenzae,Moraxella catarrh-
alis, and Streptococcus pneumoniae. Less-common non-
enteric, gram-negative organisms including Pseudomonas
aeruginosa, gram-positive organisms including Staphylo-
coccus aureus, and strains of nontuberculosis Mycobacteria
are more often seen in AECOPD/AECB episodes involving
elderly patients with frequent episodes of CB or those with
bronchiectasis. Risk-stratified antibiotic treatment guide-
lines appear useful for purulent episodes of AECOPD and
episodes of AECB. These guidelines have not been prospec-
tively validated for the general population and especially
not for the elderly population. Using a risk-stratification
approach for elderly patients, first-line antibiotics (e.g.,
amoxicillin, ampicillin, pivampicillin, trimethoprim/sulfa-
methoxazole, and doxycycline), with a more-limited spec-
trum of antibacterial coverage, are used in patients who are
likely to have a low probability of resistant organisms dur-
ing AECOPD/AECB. Second-line antibiotics (e.g., am-
oxicillin/clavulanic acid, second- or third-generation
cephalosporins, and respiratory fluoroquinolones) with a
broader spectrum of coverage are reserved for patients with
significant risk factors for resistant organisms and those
who have failed initial antibiotic treatment. J Am Geriatr
Soc 58:570–579, 2010.
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Chronic obstructive pulmonary disease (COPD), a syn-drome comprising aspects of inflammatory chronic
bronchitis (CB), including bronchiectasis, reversible air-
ways disease with small-airway obstruction, and emphy-
sema secondary to lung tissue destruction and loss of lung
recoil, is a common disease of older adults.1,2 Individual
patients will have unique contributions to their chronic
pathological lung status from the various disease compo-
nents that make up COPD. The variable contributions to an
individual patient’s clinical manifestation are particularly
noted in the interaction of the inflammatory syndromes of
CB and COPD. CB is reported in approximately 85% of
patients with severe COPD.3 The syndrome of CB can also
occur without airway obstruction. Conversely, only a mi-
nority of patients with CB have COPD, but when they co-
exist, small-airway obstructive features are present.2,3 Age
is a risk factor for COPD and CB. The complex process of
aging contributes to the risk of respiratory infections in
older adults.4,5 These age-related changes include risk of
aspiration often secondary to swallowing abnormalities or
loss of airway protection, poor nutritional status, obstruc-
tive lung processes such as mucous plugging and dynamic
airway collapse, weaker respiratory muscle function, a de-
cline in innate and adaptive cell- and humoral-mediated
immunities, and poor local or lung immunity. Collectively,
respiratory tract infections are a leading cause of morbidity
and mortality in older patients.6 Acute exacerbations of
COPD (AECOPD) are thought to have a bacterial, viral, or
mixed viral–bacterial etiology in as many as 70% of cases.7
This article will review the epidemiology, pathophys-
iology, etiology, and clinical features of acute exacerbation
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of CB (AECB) and AECOPD and specifically focus on the
role of antibiotics in the treatment of elderly patients.
DEFINING AECOPD AND AECB
COPD is a significant and growing cause of mortality and
morbidity worldwide. It was estimated that COPD was the
fifth leading cause of worldwide death in 2001 and will
become the third leading cause by 2020.8 Aging of the
world’s population and the continued use of tobacco are
thought to be responsible for the growing burden of
COPD.8 Using the Global Initiative for Chronic Obstruc-
tive Lung Disease (GOLD) criteria (forced expiratory vol-
ume in 1 second (FEV1)/forced vital capacity (FVC)o70%
with symptoms of cough and sputum production), an in-
ternational study demonstrated that the odds ratio (OR) for
the diagnosis of stage II or higher COPD was 1.94 (95%
confidence interval (CI)51.80–2.10) per 10-year incre-
ment of age.9 This compares with the OR for developing
stage II or higher COPD of 1.20 (95% CI51.14–1.25) for
each 10 pack-years of smoking.9 The adult prevalence
found in this large worldwide study was 10.1% overall,
11.8% for men and 8.5% for women, for stage II or higher
COPD.9 Because normal lung aging results in obstructive
changes, caution in interpreting spirometry of older adults
is warranted. Adjustment of the GOLD criteria have been
made and suggest that, in patients aged 70 and older, the
normal FEV1/FVC ratio should be reduced from 70% to
65% to account for the normal aging process.10
Inflammatory and immune responses to inhaled toxic
particles and gases from tobacco smoke underlie the current
theories of the pathogenesis of COPD, but other environ-
mental types of inhalation injury, airway infections and
genetic factors such as alpha-1-antitypsin deficiency con-
tribute to the risk of developing COPD.2 Although inflam-
matory changes are found in the airways of all smokers,
only a susceptible minority of these smokers develops
COPD with an amplified inflammatory and immune re-
sponse. This response is prolonged over years and decades
and is linked to lung tissue remodeling. Remodeling is also
associated with CB with small-airway bronchiolitis.2 The
resultant air flow limitations lead to hyperinflation of
the lung and air trapping in COPD. Evidence supporting the
concept of COPD as a disease of accelerated lung aging and
chronic inflammation is growing, which may indicate fu-
ture therapeutic approaches.11
A standard definition of AECOPD includes acute and
sustained worsening of the patient’s chronic stable pulmo-
nary condition that is beyond normal day-to-day varia-
tions.9,12,13 The main risk factor for AECOPD is lung
infection, but secondary risk factors include exposure to
pollutants, allergens, and sedatives; congestive heart failure
(CHF); and pulmonary embolism.14 AECOPD is associated
with bacterial airway changes in approximately half of
cases15 and viral, bacterial, or mixed viral–bacterial
changes in up to 70% of the cases.7 Bacteria in the airway
of patients with AECOPD can cause the release of antigens,
including endotoxins, peptidoglycan fragments, lipopro-
teins, and other molecules, to induce potent systemic and
local airway inflammatory effects.16 Reduction or modula-
tion of viral- or bacterial-induced inflammation has the
potential to mitigate or prevent the clinical manifestations
of AECOPD. Multifactorial causes may also precipitate
AECOPD, although in some cases no definite cause for the
exacerbation can be determined.2,14
Severe limitation of the quality of life (QOL), health-
care costs, deaths, and hospitalizations are associated with
AECOPD. High healthcare costs can be seen even before
the diagnosis of COPD is made. Retrospective analyses of
healthcare costs during the 2 years before the initial diag-
nosis of COPD were conducted. It was found that the costs
before diagnosis were $2,489 higher for Year 1 and $1,182
higher for Year 2 than for matched controls.17 Data from
2000/01 estimated that approximately 110,000 deaths,
more than 500,000 hospitalizations, and more than $18
billion in direct medical expenditures per year occurred in
the United States from AECOPD.14 AECOPD causes pro-
gressive loss of lung function with each exacerbation. The
annual rate of decline in FEV1 was approximately 20%
greater in patients with COPD with frequent (42/year)
AECOPD than those with less frequent rates.14 Greater
frequency of AECOPD is associated with greater use of
healthcare resources and lower QOL scores than in patients
with COPD without frequent AECOPD. Risk factors for
frequent AECOPD include older age, severity of FEV1 im-
pairment, chronic bronchial mucus hyperexcretion, fre-
quent past episodes of AECOPD, daily cough or wheeze,
and persistent symptoms of CB.14
Early studies of patients with COPD isolated bacterial
pathogens from the sputum at the same rates during exac-
erbations and during stable disease, causing the role of bac-
teria to be questioned.18 Recently, using molecular typing of
sputum isolates of nonencapsulated Haemophilus influen-
zae, Moraxella catarrhalis, Streptococcus pneumoniae, and
Pseudomonas aeruginosa, new strains were more frequently
isolated during AECOPD than at clinic visits without exac-
erbation, with a relative exacerbation risk of 2.15 (95%
CI51.83–2.53).18 In a recent cohort of 433 subjects with
COPD (aged 65  11), those with chronic cough and spu-
tum production consistent with CB were found to have sig-
nificantly more-frequent AECOPD episodes that required
hospitalizations than those without CB.19
CB is a progressive disease characterized by chronic
sputum production and defined by at least 3 months of
cough and sputum in each of 2 consecutive years after the
elimination of tuberculosis, lung cancer, and other causes of
cough.3,20 CB is reported in the majority of patients with
COPD.3 AECB causes recurrent attacks in these patients
associated with worsening bronchial inflammation. They
occur on average 1.5 to 3 times a year and are superimposed
on the baseline cough and sputum production. Three car-
dinal symptoms (increased daily sputum volume, a change
in sputum color (e.g., darkerFmore gray, yellow, or green),
and worsening dyspnea) define exacerbations.20 In 1987, it
was found that, in patients with COPD and AECB, those
with two or three of the previously defined symptoms had
better clinical outcomes and fewer clinical failures when
treated with antibiotics (e.g., amoxicillin, trimethoprim-
sulfamethoxazole, or doxycycline) than with placebo.21 A
meta-analysis of placebo-controlled trials of AECB and
COPD between 1957 and 1992 found an overall significant
benefit for antibiotic-treated patients.22
Recent U.S. estimates suggest that 4% to 6% of the
adult population has CB.23 Based on 1995 claims data,
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more than 90% of patients with CB sought healthcare
treatment at an estimated yearly cost of $1.6 billion for
patients aged 65 and older and $419 million for patients
younger than 65 in the United States.24 Internationally,
AECB results in more than 1.5 million annual Canadian
physician visits.3 A decline in lung function and QOL are
seen after AECB, along with an increase in patients be-
coming housebound and reporting impaired health status
and a resultant increased mortality.6,7
As previously noted, older age is a risk factor for
greater frequency of AECOPD and may explain the world-
wide rise in COPD-associated hospitalizations.25 The risk
of 90-day mortality is 3 times as great in elderly patients
admitted with AECOPD as in younger patients.26 A patient
aged 80 and older hospitalized with AECOPD has a relative
risk of death during or shortly after discharge of 3.0 com-
pared with patients younger than 65.27 The risk of devel-
oping AECB increases with age, particularly with
comorbidities such as advanced COPD, malnutrition, re-
current aspiration, cardiac disease, active smoking, recent
viral infections, alcoholism, impaired immune function,
other chronic lung conditions, and residence in a long-term
care facility.5,6,28 The prevalence of CB in the United King-
dom also increases with age. Between the ages of 25 to 44,
the prevalence is 7.5 per 10,000. It increases to 65 per
10,000 in people aged 44 to 64 and to more than 200 per
10,000 in people aged 75 to 84.28
Clinically, bronchiectasis is associated with a chronic
productive cough with recurrent or persistent infections.
Remodeling and distortion of the conducting airways by
repeated infections or profound inflammatory reactions re-
sult in dilation and scarring of the bronchi and bronchioles
and defines bronchiectasis.29 Postinfectious states (e.g., tu-
berculosis, necrotizing pneumonias, and fungal diseases),
idiopathic genetic disorders (e.g., primary ciliary dysfunc-
tion, cystic fibrosis, and alpha 1-antitrypsin deficiency),
recurrent aspiration, immune deficiency, rheumatoid arthri-
tis, ulcerative colitis, and allergic bronchopulmonary asper-
gillosis are some of the known causes of bronchiectasis.30
An association between bronchiectasis and COPD also
exists, with one study reporting that 50% of patients with
COPD with FEV1 less than 1L had evidence on high-reso-
lution chest computed tomography (CT) of bronchiecta-
sis.31 Those patients with COPD with CT evidence of
bronchiectasis clinically had more-severe episodes of AE-
COPD.31 The prevalence of non-cystic fibrosis bronchiecta-
sis in the United States determined between 1999 and 2001
was estimated to be more than 110,000 cases and ranged
from4.2 cases in 100,000 persons aged 18 to 34 to 272 cases
in 100,000 for those aged 75 and older.32 The prevalence
was higher in women than in men at all ages. Patients with
bronchiectasis required on average more days in the hospi-
tal, more days of antibiotic therapy, and higher medical care
expenditure than those without bronchiectasis.32 The bur-
den of bronchiectasis is significant in developed countries,
but the prevalence and burden of bronchiectasis is thought
to be even greater in less-developed countries.30
THE ROLE OF BACTERIA
Much of the morbidity andmortality of COPD is associated
with AECOPD. Bacteria are thought to cause half of the
episodes, with non-encapsulatedH. influenzae,M. catarrh-
alis, and S. pneumoniae representing the most common
pathogens.16,33 Bacteria often appear to be at the center of a
complicated process that involves amplification of inflam-
mation in part by bacterial antigens stimulating inflamma-
tory mediators.16 As previously noted, even in patients with
COPD with baseline sputum cultures positive for H. influ-
enzae,M. catarrhalis, S. pneumoniae, or pseudomonas, us-
ing molecular typing techniques, sputum isolated during
AECOPD tended to demonstrate evidence of new strains.18
Similar to AECOPD, several potential triggers for
AECB have been identified. These include environmental
conditions such as tobacco smoke, lack of adherence to
COPD therapies, and worsening congestive heart failure
(CHF), although infections, including those from bacteria,
viruses, and atypical pathogens, are likely to cause 80% of
AECB. Bacterial infections represent the majority of caus-
ative organisms. Several respiratory viruses are associated
with approximately 30% of exacerbations, and atypical
bacteria (mostly Chlamydia pneumoniae) are implicated in
less than 10%.34 The viral pathogens found in AECB in-
clude influenza, parainfluenza, rhinovirus, coronavirus, ad-
enovirus, and respiratory syncytial virus.34 The four major
bacterial causes of AECB, including those in elderly pa-
tients, are S. pneumoniae,H. influenzae,H. parainfluenzae,
and M. catarrhalis.3,6 Less commonly, Staphylococcus
aureus, Pseudomonas, and members of the Enter-
obacteriaceae family can be isolated during AECB.3 A
study of patients requiring mechanical ventilation for
AECB or AECOPD reported frequently isolating Gram-
negative enteric bacilli, Pseudomonas, and Stenotropho-
monas spp.6,35 The degree of measured baseline airway
obstruction tends to predict the bacterial organisms that
will be isolated from sputum obtained during AECB.6
When patients were classified according to baseline FEV1,
patients with less-severe baseline airway obstruction were
more often found to have S. pneumoniae, and other gram-
positive cocci, whereas more-severe baseline airway
obstruction was associated with H. influenzae and M.
catarrhalis. The patients with the worst baseline FEV1 had
greater likelihood of having Pseudomonas and Enter-
obacteriaceae spp. Isolated from their sputum during their
episodes of AECB/AECOPD. These patients also tended to
have other risk factors for gram-negative organisms in their
sputum, including recent hospitalizations and the use of
mechanical ventilation.36
Frequently, sputum from patients with bronchiectasis
during AECB demonstrates nonenteric gram-negative bac-
teria on culture. Reviews have reported the isolation in the
sputum of H. influenzae in 30% to 47%, Pseudomonas
aeruginosa (including mucoid species) in 12% to 31%,
M. catarrhalis in 2.4% to 20%, S. pneumoniae in 7% to
10%, S. aureus in 4% to 14%, Mycobacterium (primarily
Mycobacterium-avium intracellulare complex) in 2% to
17%, and no organism in 21% to 23% of patients with
bronchiectasis during exacerbations.29
The pathogens isolated from patients during AECB,
particularly in those with bronchiectasis, unfortunately
often demonstrate significant antibiotic resistance patterns
to penicillin, beta-lactams, macrolides, and trimethoprim/
sulfamethoxazole.37,38 The sputum isolates of elderly pa-
tients also resultmore frequently in drug-resistant pathogens
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such as multiple drug–resistant S. pneumoniae than those of
younger patients.39 In addition, during AECB/AECOPD,
older patients are more likely than younger patients to have
H. influenzae and P. aeruginosa cultured from their spu-
tum.37 More than 50% of fluoroquinolone-resistant S.
pneumoniae strains isolated were in patients aged 65 and
older.40 The emergence of plasmid-mediated fluoroquino-
lone gram-negative resistance is a worldwide problem.41
DIAGNOSTIC CRITERIA AND SEVERITY OF AECB
AND AECOPD
The cardinal or major symptoms of increased sputum vol-
ume, sputum purulence, and worsening dyspnea can be
used to classify clinical severity of AECB. Older age and the
severity of the underlying lung disease are associated with
greater frequency of AECB.6 The most-severe AECB is la-
beled Type I when all three of the major symptoms are
present.21 Type II AECB exhibits two of the three major
symptoms. Type III includes only one of these symptoms
and at least one of the minor symptoms of a respiratory
tract infection occurring within 5 days (e.g., increased
wheezing, increased cough, fever, or a 20% increase in re-
spiratory or heart rate).21 It has been argued that this system
classifies the likelihood of bacterial infection as the cause of
an exacerbation and is not really a severity scale.42
The GOLD guideline provides a spirometric classifica-
tion of disease severity for COPD.43 Using these guidelines,
Stage I is mild COPD, with FEV1 greater than 80% of pre-
dicted values. Stage II is moderate COPD, with FEV1 be-
tween 50% and 80% of predicted values. Stage III is severe
COPD, with FEV1 between 30% and 50% of predicted
values. Stage IV is the most-severe COPD, with FEV1 less
than 30% of predicted values or evidence of chronic respi-
ratory failure with FEV1 less than 50% of predicted values.
Exacerbations of COPD are defined as changes in the pa-
tient’s baseline dyspnea, cough, or sputum that are acute in
onset and beyond normal day-to-day variation of the dis-
ease.43 The GOLD guidelines further stratify patients with
AECOPD and purulent sputum based on the presence of the
same three cardinal symptoms of increased dyspnea, spu-
tum volume, and sputum purulence used in defining epi-
sodes of AECB. This further stratification, along with the
need for invasive or noninvasive mechanical ventilation, is
used to determine the need for and the choice of antibiotics
based on the potential pathogens involved during AE-
COPD. Consideration of likely organisms, the resistance
patterns of the likely organisms, and strategies to reduce
further development of resistance are key components when
considering whether andwhich antibiotic to initiate in older
patients with AECB or AECOPD.
Evidence for the use of antibiotics in patients undergo-
ing Type I or II AECB exists.3 Several guidelines have been
developed for AECB that use risk stratification in recom-
mending antibiotics. Some of these guidelines have been
promoted for elderly patients without specific data on this
population.3,44 A recent review of international guidelines
for antibacterial treatment of AECB based on risk stratifi-
cation concluded that most are similar.45 The Canadian
Thoracic Society (CTS) has developed a guideline based on
a risk-stratification system that has three categories for as-
sessment and treatment of patients with AECB.3 Group I or
‘‘simple CB’’ describes patients of any age who demonstrate
the three cardinal signs of bronchitis severity and have
fewer than four exacerbations per year, with an FEV1
greater than 50% of predicted and have no history of car-
diac disease (Table 1). Group II or ‘‘complicated CB’’ de-
scribes patients who meet simple CB (Group I) criteria plus
have one or more of the following risk factors: FEV1 of less
than 50% of predicted value, more than four exacerbations
per year, a history of cardiac disease, supplemental oxygen
use, long-term oral corticosteroid use, or antibiotic use
within the previous 3 months.3 The final Group III or
‘‘chronic suppurative’’ category describes patients who
meet the criteria of Group II plus have chronic purulent
sputum production or more than four exacerbations per
year, require antibiotics more than four times per year (of-
ten within the previous 3 months), have a baseline FEV1 less
than 35% of predicted value, and may have multiple of
these risk factors (Table 1). A prospective study used patient
stratification to define antibiotic treatment in AECB
and demonstrated that patients with complicated CB exac-
erbations had lower clinical and microbiological success
rates than patients with simple or uncomplicated CB
exacerbations.46
In addition to classifying AECB, the CTS also classifies
AECOPD as a purulent or nonpurulent event.47 Purulent
AECOPD episodes are further defined as simple or com-
plicated exacerbations. Simple AECOPD has increased
sputum purulence and dyspnea, whereas complicated AE-
COPD has the features of simple plus at least one of the
following risk factors for poor outcome: FEV1 less than
50% predicted, more than four exacerbations per year, is-
chemic heart disease, use of home oxygen, or chronic oral
steroid use.
Table 2 summarizes the GOLD guidelines for the caus-
ative organisms associated with AECOPD. Group A epi-
sodes are mild events, rarely require hospitalization, have
only one cardinal symptom of CB, and have no risk factors
for poor outcome.43 Groups B and C AECOPD are likely to
require hospitalization, are increasingly severe events, have
increasing risk factors for poor outcome, and in the case of
Group C, have risk factors for P. aeruginosa.
Table 1. Canadian Thoracic Society and Canadian
Infections Disease Society Chronic Bronchitis (CB) Strat-
ification System3
Category of CB Clinical Characteristics
Group 0 (acute
tracheobronchitis)
Cough and sputum without previous pulmonary disease
(patients do not meet definition of CB)
Group I (simple CB) o4 exacerbations/year (meets definition of CB)
FEV1450% predicted
Group II (complicated
CB)
FEV1o50% predicted
FEV1 50–65% predicted and significant comorbidity:
congestive heart failure, coronary artery disease, or
44 exacerbations/year
Group III (suppurative
CB)
As in Group II but with constant purulent sputum
Frequent exacerbation (44/year) may have
bronchiectasis
FEV1o50% predicted (usuallyo35% predicted)
FEV15 forced expiratory volume in 1 second.
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NONANTIBIOTIC THERAPY FOR ELDERLY
PATIENTS WITH AECOPD/AECB
Because of the significant overlap between the syndromes of
AECOPD and AECB, the discussed nonantibiotic treatment
approach in elderly patients will be combined in this article.
The acute use of inhaled bronchodilators represents a
mainstay of treatment in patients with evidence of airway
obstruction. Short-acting inhaled beta2-agonists appear to
be the preferred initial bronchodilator for the treatment of
AECOPD, although prospective placebo-controlled trials
have not been performed.48 The short-acting anti-
cholinergic agent ipratropium bromide can be added to
the treatment regiment. A meta-analysis has shown that, in
AECOPD, there is no significant difference between the re-
sults of inhaled short-acting beta2-agonists or short-acting
anticholinergics.49 Although commonly used, the combi-
nation of a short-acting beta2-agonist with a short-acting
anticholinergic has not uniformly been shown to improve
outcomes in AECOPD.48,49 Nebulizer-based delivery of
these agents appears to be as effective as using a metered-
dose inhaler with a spacer in patients with AECOPD.48 The
use of intravenous aminophylline, a methylxanthine, in the
treatment of AECOPD is controversial, and no consistent
benefits have been demonstrated.48 The frequent presence
of comorbidities, particularly cardiovascular comorbidities
in elderly patients with AECOPD, must be considered be-
fore using high-dose inhaled beta2-agonist treatment or in-
travenous methylxanthines.50,51 Ensuring appropriate but
not excessive hydration of older patients with exacerbations
of COPD or CB can reduce the thickness of the sputum and
aid clearance. Supplemental oxygen therapy to ensure an
arterial oxygen tension greater than 60mmHg has been
advocated.48 A recent meta-analysis of the treatment of
AECOPD has demonstrated that systemic corticosteroids
are effective in reducing treatment failures and that the use
of noninvasive positive pressure ventilation can reduce the
need for intubation and mortality.52
In addition to the chronic use of bronchodilators and
inhaled corticosteroids, domiciliary oxygen therapy has
been shown to improve survival in COPD. Participation in
pulmonary rehabilitation can improve the health status of
elderly patients with COPD, CB, or both.53 Smoking ces-
sation and pneumococcal and influenza vaccinations are
also important preventive measures in elderly patients with
COPD, CB, or both.43,53 Intravenous replacement therapy
(e.g., immunoglobulin G or alpha-1 antitrypsin infusions)
has been used in patients with appropriately deficient
bronchiectasis, but data on elderly patients are scarce. Me-
chanical and pharmacological techniques for the mobiliza-
tion of secretions in these patients appear to be important
adjunctive treatments.29,30
ANTIBIOTIC TREATMENT IN ELDERLY PATIENTS
WITH AECOPD AND AECB
Using a risk-stratification approach that includes comor-
bidity evaluation and determination of recent exposure to
antibiotics appears central to the various guidelines for the
selection of antibiotics in the treatment of episodes of
AECOPD and AECB. Unfortunately, prospective outcome-
based trials have yet to be done to confirm these expert
consensus guidelines, and in general, no subset analyses on
elderly patients are reported in the many recent industry-
sponsored noninferiority trials.
Because bacteria cause as many as 50% to 70% of
AECOPD episodes,7,15 it has been stressed that, in ap-
proaching older patients with AECOPD, it is important to
evaluate the severity of the exacerbation using the three
Table 2. Global Initiative for Chronic Obstructive Lung Disease Guidelines for Acute Exacerbations of Chronic
Obstructive Pulmonary Disease (AECOPD) Severity and Need for Antibiotics
AECOPD
Category Hospitalization Exacerbation Clinical Organisms Antibiotics
A No Mild  No risk factors for poor outcome
No comorbidity
No frequent exacerbations
No severe Stage IV COPD
No recent antibiotic use
 Only one cardinal symptom of chronic bronchitis
H. influenzae
S. pneumoniae
M. catarrhalis
C. pneumoniae
Viruses
No
B Yes Moderate  Risk factors(s) for poor outcome
 No risk factor for P. aeruginosa infection
Group A plus
penicillin-resistant S. pneumoniae
Enterobacteriaceae
Klebsiella pneumoniae
Escherichia coli
Proteus
Enterobacter
Yes
C Yes Severe  Risk factor(s) for poor outcome and P. aeruginosa
infection
Recent hospitalization
Frequent administration of antibiotics (4
courses in previous year)
Stage IV COPD
Isolation of P. aeruginosa during previous
exacerbation or during a stable period
Group B plus P. aeruginosa Yes
Adapted from GOLD Guidelines.43
574 ALBERTSON ET AL. MARCH 2010–VOL. 58, NO. 3 JAGS
cardinal symptoms of CBFincreased sputum volume, in-
creased purulence, and increased dyspnea from baseline.15
Furthermore, consideration of underlying comorbidities,
underlying severity of lung disease, and the frequency of
exacerbations help determine whether the episode is a
‘‘simple’’ or ‘‘complicated’’ AECOPD. Table 3 outlines the
risk-stratified CTS guidelines for antibiotic treatment in
patients with purulent sputum–associated AECOPD. It is
recommended that cases of simple AECOPD with purulent
sputum be treated with amoxicillin, second- or third-gen-
eration cephalosporins, doxycycline, extended-spectrum
macrolides, or trimethoprim/sulfamethoxazole.15,47 The
antibiotic treatment recommended for purulent AECOPD
classified as ‘‘complicated’’ includes the respiratory fluoro-
quinolones (gemifloxacin, levofloxacin, and moxifloxacin)
and beta-lactam/beta-lactamase inhibitor agents such as
amoxicillin/clavulanate. Sputum culture–guided therapy
may be useful in this group.
A meta-analysis of randomized controlled trials on the
use of antibiotics in AECOPD (N51,020, mean age 67)
concluded that antibiotic treatment significantly reduced
treatment failures and in-hospital mortality.52 Short-course
antibiotic treatment approaches (o5 days) were evaluated in
a 21-study meta-analysis in AECOPD and AECB. Short
courses of antibiotics were just as effective as the traditional
longer treatment courses in patients with mild to moderate
AECOPD and AECB.55 In addition to the acute use of mac-
rolide antibiotics in the treatment of ‘‘simple’’ AECOPD as-
sociatedwith purulent sputum, the chronic use ofmacrolides
has been evaluated for its ability to immunomodulate and
potentially prevent AECOPD. Data exist that support
the use of prolonged macrolide antibiotics in a number
of chronic inflammatory lung conditions (diffuse pan-
bronchiolitis, asthma, non-cystic fibrosis–associated
bronchiectasis, and cystic fibrosis). The data in patients with
COPD have been limited and somewhat supportive.56,57
In evaluating acute bronchitis and AECOPD in elderly
patients (average age 75), Dutch investigators found that
general practitioners prescribed antibiotics to the majority
of cases of acute bronchitis (84%) and AECOPD (53%).
When prescribing antibiotics to elderly patients with acute
bronchitis, no association with comorbid conditions was
found.58 Antibiotics were more often prescribed for
AECOPD in patients with diabetes mellitus and heart fail-
ure. The authors called for practitioners to better follow
published comorbidity risk-stratified guidelines, which
would have greatly limited treatment of acute bronchitis.58
Antibiotics selected using a risk-stratification approach
involving comorbidity analysis have been advocated in
treating AECB in elderly patients.6 Similar to AECOPD,
risk-stratification-based guidelines for the treatment of
AECB treat lower-risk patients with classes of antibiotics
with narrow spectrums of antibacterial coverage (first-line).
Several antibiotic guidelines for the treatment of AECB
have been published.3,6,45 These consensus-based guide-
lines have not been prospectively validated, and no specific
outcome-based data exist for older patients.
A meta-analysis compared first-line with second-line
antibiotics in the treatment of AECB.59 Mean ages of the
patients in the 12 randomized controlled trials examined
ranged from 49 to 71. Second-line antibiotics (e.g., am-
oxicillin/clavulanic acid, second- or third-generation
cephalosporins, and fluoroquinolones) were more effective
and just as safe as first-line antibiotics (e.g. amoxicillin,
ampicillin, pivampicillin, trimethoprim/sulfamethoxazole,
and doxycycline).59 A more-detailed analysis of antibiotic
effectiveness stratified according to risk factors for poor
outcomes including advanced age could not be done be-
cause of a lack of data. Another meta-analysis of 19 trials
comparing antibiotic treatments in AECB found that mac-
rolides, fluoroquinolones, and amoxicillin/clavulanate were
equivalent in their short-term effectiveness,60 although the
use of fluoroquinolones demonstrated better microbiolog-
ical success with fewer recurrences of AECB than macrol-
ides. The use of amoxicillin/clavulanate was found to be
associated with more adverse effects than the use of fluoro-
quinolones or macrolide antibiotics.60 Again, further risk
stratification including age could not be done. A third meta-
analysis of five randomized controlled trials on the use of
the semisynthetic penicillins (e.g., amoxicillin, ampicillin,
and pivampicillin) and trimethoprim-based regimens (e.g.,
trimethoprim, trimethoprim-sulfamethoxazole, and trime-
thoprim-sulfadiazine) found that they had equivalent effec-
tiveness and toxicity in treating AECB.61 The various
Table 3. Canadian Antibiotic Recommendations for Purulent Acute Exacerbations of Chronic Obstructive Pulmonary
Disease (COPD)54
Category Clinical State Symptoms and Risk Factors Pathogens Antibiotics
Simple exacerbation COPD without risk
factors
Increased mucopurulent sputum and
dyspnea
H. influenzae
H. species
S. pneumoniae
M. catarrhalis
Amoxicillin
Cephalosporins (2nd/3rd generation)
Doxycycline
Macrolides (extended-spectrum)
Trimethoprim/sulfamethoxazole
(in alphabetical order)
Complicated
exacerbation
COPD with risk
factors
As in simple, plus at least one of the
following:
 forced expiratory volume in 1
second o50% predicted
 Ischemic heart disease
 Use of home oxygen
 Chronic oral corticosteroid use
As in simple plus:
 Klebsiella species and
gram-negative
 Increased probability of
beta-lactam resistance
 Pseudomonas species
Respiratory fluoroquinolone
(gemifloxacin, levofloxacin, or
moxifloxacin)
Beta-lactam/beta-lactamase inhibitor
(in order of preference)
Repeat course of antibiotics of the same class should be avoided within a 3-month interval.
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guidelines for treating AECB are similar in their recom-
mendations.45 The current CTS antibiotic guidelines for
treating AECB are summarized in Table 4 and are similar to
their antibiotic guidelines for AECOPD with purulent spu-
tum (Table 3).
A specific meta-analysis of randomized controlled trials
of AECB has found that short courses of antibiotics (o5
days) are as effective as and safer than long-duration
antimicrobial treatments.62 Antibiotic courses as short as 3
days have been shown to be as effective as long-duration
courses of comparator antibiotics in 12 randomized con-
trolled trials.63 Early initiation of antibiotics appears im-
portant in patients requiring hospitalization. When
antibiotics were started before elderly patients (average
age 75) reached the hospital, those hospitalized for AECB
or AECOPD had lower short-term mortality.64
The CTS guidelines for Group III or suppurative CB
with adjustment of the selection of oral or parenteral an-
tibiotics based on previous or current sputum culture results
appear appropriate for most elderly patients with
bronchiectasis.3 Because of frequent P. aeruginosa infec-
tions in these patients, the nonrespiratory fluoroquinolone
ciprofloxacin (oral or intravenous), together with other in-
travenous antipseudomonal agents, is frequently prescribed
in an attempt to reduce the emergence of fluoroquinolone-
resistant P. aeruginosa organisms. Inhaled tobramycin lacks
Food and Drug Administration approval and lacks proven
efficacy in patients with non-cystic fibrosis bronchiecta-
sis.29–31 Specialty consultation is often required when treat-
ing elderly patients with bronchiectasis after isolation of
non-tuberculosis mycobacteria.29
Table 5 summarizes recent randomized controlled
comparative antibiotics trials in the treatment of AECB.
All of these trials were designed as noninferiority trials and
for the most part are industry sponsored. Only three of the
13 trials enrolled patients with mean ages of 65 and older.
Only two of the 13 trials demonstrated statistical difference
in outcomes.65,66 In reviewing these recent trials, mo-
xifloxacin was shown to have a small but significantly better
‘‘clinical cure’’ rate than comparator antibiotics in AECB.65
The same study showed a 14-day-longer interval to the next
exacerbation with moxifloxacin.65 In a second trial, gem-
ifloxacin also demonstrated a small but statistically better
clinical cure rate than comparator antibiotics in hospital-
ized patients with AECB.66 Gemifloxacin treatment was
associated with a 2-day reduction in hospitalization.66 The
limited size of the studies in Table 5, the lack of detailed risk
stratification, and the limited number of older patients
makes direct application of their results to older patients
difficult.
When selecting antibiotic treatment in elderly patients
with AECB, several considerations beyond the use of risk-
stratified guidelines must be made. Potential alterations in
pharmacokinetics and pharmacodynamics of agents as a
result of disease- or age-related decreases in renal and met-
abolic drug clearances and the potential for drug interac-
tions must be evaluated. The final antibiotic selection, as
well as any special monitoring and dosing requirements,
must be carefully considered because of the potential com-
plexity of older patients.
CONCLUSIONS
COPD is a syndrome unique in each patient and consists of
elements of CB, bronchiectasis, emphysema, and reversible
airway disease. Elderly patients (65) are at high risk for
COPD with CB and bronchiectasis. Episodes of AECOPD
and AECB are associated with viral, bacterial, and atypical
organisms, along with environmental factors acting as trig-
gers. Elderly patients also have greater risk for resistant
bacterial organisms such as multiple drug–resistant S. pneu-
moniae, and nonenteric gram-negative organisms such as
H. influenzae, Stenotrophomonas spp., and P. aeruginosa.
Although not prospectively validated, risk-stratified antibi-
Table 4. Antibiotic Recommendations for Acute Exacerbations of Chronic Bronchitis (CB) Based on a Canadian
Risk-Stratification System3
Category Antibiotic Recommendation
Group 0 (acute
tracheobronchitisFpatients
who do not meet definition of CB)
No first-line oral antibacterial therapy unless symptoms persist for410 to 14 days
Alternative for treatment failure: macrolide or tetracycline
Group I (simple CB) First-line oral antibacterial therapy: second-generation macrolide, second- or third-generation cephalosporin, amoxicillin, and
doxycycline
Alternative for treatment failures: respiratory fluoroquinolone (gemifloxacin, levofloxacin, or moxifloxacin) or beta-lactam/beta-
lactamase inhibitor
Group II (complicated CB) First-line oral antibiotic therapy: respiratory fluoroquinolone (gemifloxacin, levofloxacin, or moxifloxacin) or beta-lactam/beta-
lactamase inhibitor
Alternative for treatment failure:
Parenteral therapy (home or hospital)
Sputum culture-based or adjusted therapy
Consider referral to specialist
Group III (suppurative CB) First-line oral antibacterial therapy:
adjust ambulatory treatment based on sputum cultures, treat P. aeruginosaForal ciprofloxacin if sensitive
Parenteral therapy (hospital or home based) adjusted according to culture results
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otic guidelines appear helpful in directing the treatment of
AECOPD and AECB, but these have not specifically been
designed for the aging population. Antibiotic risk-stratified
guidelines have been generated as a consensus process and
have not specifically been designed for the elderly popula-
tion. Recent antibiotic studies have not reported specific
outcomes in elderly patients and are often noninferiority-
designed studies with small numbers of subjects. In general,
antibiotic treatment of AECOPD and AECB appears to be
beneficial and warranted in individual patients who may
need more-aggressive and -comprehensive care. Further
work directed specifically at antibiotic therapy for elderly
patients experiencing AECOPD and AECB is needed to es-
tablish valid outcome-based risk-stratified antibiotic guide-
lines for this population. The optimal strategy for managing
AECOPD and AECB requires long-term interventional
studies aimed at preventing frequent acute exacerbations
and hospitalizations.
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wDose of clavulanate was not always specified.
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